Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY10 | O00398 | 10/20 | 0.56 |
| ▸ | GPR34 | Q9UPC5 | 4/20 | 0.55 |
| ▸ | GPR174 | Q9BXC1 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3409912 | 1.00 | P2RY10 (0.56) | P2RY10GPR34GPR174 | |
| SCHEMBL28206519 | 1.00 | P2RY10 (0.56) | P2RY10GPR34GPR174 | |
| SCHEMBL3406657 | 0.99 | P2RY10 (0.57) | P2RY10GPR34GPR174 | |
| SCHEMBL235835 | 0.93 | P2RY10 (0.66) | P2RY10GPR34GPR174 | |
| SCHEMBL234318 | 0.93 | P2RY10 (0.66) | P2RY10GPR34GPR174 | |
| SCHEMBL3409659 | 0.92 | P2RY10 (0.60) | P2RY10GPR34GPR174 | |
| SCHEMBL25252924 | 0.87 | PLA2G2C (0.48) | P2RY10GPR34 | |
| SCHEMBL235778 | 0.87 | PLA2G2C (0.48) | P2RY10GPR34 | |
| SCHEMBL1296680 | 0.86 | PLA2G2C (0.49) | P2RY10GPR34 | |
| SCHEMBL1296985 | 0.86 | PLA2G2C (0.49) | P2RY10GPR34 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240408032-A1 | LIPID-BASED RNA FORMULATIONS SUITABLE FOR THERAPY | BioNTech SE (DE) | 2024-12-12 | — | — | US | claimed |
| EP-4398882-A1 | LIPID-BASED RNA FORMULATIONS SUITABLE FOR THERAPY | BioNTech SE (DE) | 2024-07-17 | — | — | EP | claimed |
| WO-2023036960-A1 | LIPID-BASED RNA FORMULATIONS SUITABLE FOR THERAPY | BioNTech SE (DE) | 2023-03-16 | — | — | WO | claimed |
| US-20240408032-A1 | LIPID-BASED RNA FORMULATIONS SUITABLE FOR THERAPY | BioNTech SE (DE) | 2024-12-12 | — | — | US | disclosed |
| EP-4398882-A1 | LIPID-BASED RNA FORMULATIONS SUITABLE FOR THERAPY | BioNTech SE (DE) | 2024-07-17 | — | — | EP | disclosed |
| CN-118265522-A | Lipid-based RNA formulations suitable for treatment | 生物技术欧洲股份公司 | 2024-06-28 | — | — | CN | disclosed |
| US-20230302154-A1 | NANODRUGS FOR TARGETED DRUG DELIVERY AND USE THEREOF | UNIVERSITY OF CONNECTICUT | 2023-09-28 | — | — | US | disclosed |
| WO-2023036960-A1 | LIPID-BASED RNA FORMULATIONS SUITABLE FOR THERAPY | BioNTech SE (DE) | 2023-03-16 | — | — | WO | disclosed |
| US-20220193108-A1 | Immunotherapeutic Nanoparticles And Methods Relating Thereto | WAKE FOREST UNIVERSITY HEALTH SCIENCES | 2022-06-23 | — | — | US | disclosed |
| WO-2022040435-A1 | NANODRUGS FOR TARGETED DRUG DELIVERY AND USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-02-24 | — | — | WO | disclosed |
| WO-2020210317-A1 | IMMUNOTHERAPEUTIC NANOPARTICLES AND METHODS RELATING THERETO | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2020-10-15 | — | — | WO | disclosed |
| WO-2010126319-A2 | LIPOPEPTIDE WITH SPECIFIC AFFINITY TO THE FC REGION OF AN ANTIBODY, AND ANTIGEN-RECOGNIZING LIPID NANOPARTICLE COMPRISING SAME | 고려대학교 산학협력단 (KR) | 2010-11-04 | — | — | WO | disclosed |
| US-7785568-B2 | Sterically stabilized liposomes with hydrophilic polymers on surface; computed tomography | MARVAL BIOSCIENCES, INC. (US) | 2010-08-31 | — | — | US | disclosed |
| WO-2010053489-A1 | FUSOGENIC PROPERTIES OF SAPOSIN C AND RELATED PROTEINS AND PEPTIDES FOR APPLICATION TO TRANSMEMBRANE DRUG DELIVERY SYSTEMS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2010-05-14 | — | — | WO | disclosed |
| EP-2081552-A2 | SPONTANEOUSLY FORMING ELLIPSOIDAL PHOSPHOLIPID UNILAMELLAR VESICLES | Children's Hospital Medical Center (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-2020988-A2 | COMPOSITIONS COMPRISING FUSOGENIC PROTEINS OR POLYPEPTIDES DERIVED FROM PROSAPOSIN FOR APPLICATION IN TRANSMEMBRANE DRUG DELIVERY SYSTEMS | Children's Hospital Medical Center (US) | 2009-02-11 | — | — | EP | disclosed |
| US-20080131369-A1 | Sterically stabilized liposomes with hydrophilic polymers on surface; computed tomography | MARVEL THERAPEUTICS (US) | 2008-06-05 | — | — | US | disclosed |
| WO-2008051818-A2 | SPONTANEOUSLY FORMING ELLIPSOIDAL PHOSPHOLIPID UNILAMELLAR VESICLES | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2007127439-A2 | COMPOSITIONS COMPRISING FUSOGENIC PROTEINS OR POLYPEPTIDES DERIVED FROM PROSAPOSIN FOR APPLICATION IN TRANSMEMBRANE DRUG DELIVERY SYSTEMS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070212303-A1 | Sterically stabilized liposomes with hydrophilic polymers on surface; computed tomography | MARVAL PHARMA, INC. | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240408032-A1 | LIPID-BASED RNA FORMULATIONS SUITABLE FOR THERAPY | PHOSPHO1, PLIN3, SARNP | P2RY10 4300/4885GPR34 4287/4885GPR174 3568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.